retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial π¨ Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. π Mean body weight change at 80 weeks: β¬οΈ Cagrilintide vs Retatrutide Compared |
Pay in 4 interest-free payments of $5.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 11 - Aug 16








![Science & Tech Spotlight: COVID-19 Vaccine Development [Updated on June 29, 2021]](https://www.gao.gov/assets/extracts/39d04e393df735a64e55d828648b360b/COVID-19-Experimental-Vaccine-2-1.png)
















